Immunic Inc (NASDAQ:IMUX) told investors it has received a Notice of Allowance from the US Patent and Trademark Office for a patent application protecting the treatment of relapsing multiple sclerosis (RMS).
The company said in a statement that patent application 17/391,442, entitled, "Treatment of Multiple Sclerosis Comprising DHODH Inhibitors," covers a daily dose of about 10 mg to 45 mg of vidofludimus calcium (IMU-838) and other salts as well as free acid forms for the treatment of RMS.
Immunic noted that vidofludimus calcium is covered by several layers of granted patents in the US, Europe and other jurisdictions around the world. These patents are directed towards composition-of-matter for salt forms of vidofludimus calcium, including the specific salt form used in Immunic's clinical trials, as well as the dose strength used in clinical trials for the treatment of RMS.
The patents provide protection in the US into 2041 unless extended further, the company added.
"Allowance of this patent, covering the dose strength of vidofludimus calcium for the treatment of RMS, including the 30 mg dosage used in our ongoing twin phase 3 ENSURE trials, significantly bolsters the multilayered proprietary intellectual property position we have strategically built around our lead, late-stage program for patients with multiple sclerosis," Immunic president and CEO Dr Daniel Vitt said in a statement.
”Importantly, this patent for the dose strength in RMS patients covers all salt and free acid forms of vidofludimus calcium. We remain committed to protecting the technology around this phase 3 asset, in order to assure extended exclusivity upon potential regulatory approval from the US Food and Drug Administration.”
Immunic is a biotechnology company developing a clinical pipeline of orally-administered, small-molecule therapies for chronic inflammatory and autoimmune diseases.
Contact the author at stephen.gunnion@proactiveinvestors.com